Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Loxo Oncology Inc.

    Client Virtual Booth

    LOXO ONCOLOGY INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Loxo Oncology Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    281 Tresser Blvd, 9th Floor Stamford, CT 06901
    Telephone
    Telephone
    +1 203.653.3880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.loxooncology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/loxo-oncology-inc-/
    Twitter
    Twitter
    https://twitter.com/loxooncology?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

    Details:

    The collaboration includes co-development and co-commercialization agreement for Foghorn’s selective BRM oncology program and undisclosed oncology target. The collaboration includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control platform.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Small molecule

    Recipient: Foghorn Therapeutics

    Deal Size: $380.0 million Upfront Cash: $300.0 million

    Deal Type: Collaboration December 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lilly Presents New Data on Retevmo in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 AACR Annual Meeting

    Details:

    First-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising antitumour activity and safety in various RET fusion-positive advanced solid tumours. Safety consistent with known profile of Retevmo.


    Lead Product(s): Selpercatinib

    Therapeutic Area: Oncology Product Name: Retevmo

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Recipient: Eli Lilly

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 11, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305

    Details:

    In the 121 efficacy-evaluable BTK-pretreated patients, the ORR was 62%. This deepening of response over time is consistent with other BTK inhibitors and suggests the overall efficacy profile of LOXO-305 will continue to strengthen with additional follow-up.


    Lead Product(s): Loxo-305

    Therapeutic Area: Oncology Product Name: LOXO-305

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Eli Lilly

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting

    Details:

    LOXO-305 oral presentations will provide updated data from the ongoing Phase 1/2 BRUIN clinical trial in previously treated chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, and other non-Hodgkin lymphomas.


    Lead Product(s): Loxo-305,Venetoclax,Rituximab

    Therapeutic Area: Oncology Product Name: LOXO-305

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 05, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search